JNJ logo
Johnson & Johnson
JNJ
195.93 (0.75%) 1.47
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of various products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as immunology including rheumatoid arthritis psoriatic arthritis inflammatory bowel disease and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience consisting of mood disorders neurodegenerative disorders and schizophrenia; oncology such as prostate cancer hematologic malignancies lung cancer and bladder cancer; cardiovascular and metabolism including thrombosis diabetes and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips knees trauma spine sports and other; surgery portfolios comprising advanced and general surgery technologies as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers hospitals and retailers as well as physicians nurses hospitals eye care professionals and clinics. The company was founded in 1886 and is based in New Brunswick New Jersey.

Quality Checklist 6/8

5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $472.05(B)
EV: $503.93(B)
Total Equity: $79.28(B)
Earnings date: Jan-21-2026
P/E: 18.79
Forward P/E: 18.04
P/FCF: 24.07
P/S: 5.12
P/B: 5.95
EPS: $10.4
EPS (fwd): $10.9
FCF/share: $8.1
Revenue/share: $38.3
Book value/share: $33.0
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.58
Current Ratio: 1.10
Gross margin: 68.3%
Operating margin: 26.2%
Net margin: 27.3%
Dividend/share: $5.1
Div. yield: 2.59%

JNJ Valuation & Price Targets

Current Price
$196

Favorite Valuation Methods

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

21% overvalued
Low
$117
Mid
$155
High
$194
Current price
$196
Fair P/E
Margin of safety
EPS
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+110.810.911.025
FY+211.111.511.926
FY+311.712.413.321
FY+412.713.214.48
FY+513.214.315.57

Analyst Price Targets

4% undervalued
Low
$155
Mid
$205
High
$230
Current price
$196

Analyst Recommendations

Strong Buy4
Buy9
Hold11
Sell0
Strong Sell1

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate